Consistently with previous reports, the frequency of alterations in AR and HRR genes including BRCA2 and ATM was enriched in mCRPC compared with mCSPC, suggesting that alterations in AR and HRR genes promote treatment resistance to initial ADT-based therapy in prostate cancer. This evidence concerns the gene BRCA2 and prostate cancer.